- Home
- PHAR vs ACEL Comparison
PHAR vs ACEL Comparison
Compare PHAR & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | ACEL |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 942.7M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PHAR | ACEL |
|---|---|---|
| Price | $17.10 | $10.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $38.00 | $14.00 |
| AVG Volume (30 Days) | 32.4K | ★ 280.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | N/A |
| Revenue This Year | $27.75 | $9.75 |
| Revenue Next Year | $9.39 | $4.29 |
| P/E Ratio | $3,041.22 | ★ $26.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.50 | $9.02 |
| 52 Week High | $21.34 | $12.92 |
Technical Indicators
Market Signals| Indicator | PHAR | ACEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 41.45 |
| Support Level | $16.35 | $10.13 |
| Resistance Level | $17.08 | $11.63 |
| Average True Range (ATR) | 0.57 | 0.28 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 77.74 | 16.35 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.